Bluebird Bio Cmn (BLUE) 73.81 $BLUE LentiGlobin
Post# of 273254
Posted On: 09/22/2016 7:04:17 AM
Bluebird Bio Cmn (BLUE) 73.81 $BLUE
LentiGlobin(TM) Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency's PRIME Program
BusinessWire - Wed Sep 21, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for LentiGlobin drug product in the treatment of patients with transfusion-dependent beta-thalassemia (TDT).
BLUE: 73.81 (+0.04)
InvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, AMGN, BLUE, CSC, and EXPE.
BLUE: 73.81 (+0.04), ALDR: 35.12 (+0.98), CSC: 51.36 (+2.05), EXPE: 108.02 (+0.37), AMGN: 173.85 (+0.47)
bluebird bio (BLUE) in Focus: Stock Moves 11.4% Higher
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 7:25AM CDT
bluebird bio, Inc. (BLUE) moved big last session, as its shares jumped a little over 11% on the day.
BLUE: 73.81 (+0.04), GERN: 2.25 (+0.20)
bluebird bio Stock Up on Start of Phase III LentiGlobin Study
Zacks Equity Research - Zacks Investment Research - Fri Sep 09, 9:02AM CDT
bluebird bio, Inc. (BLUE) announced the commencement of a phase III study on its experimental gene therapy, LentiGlobin. Shares of the biotech company were up almost 9% yesterday on the news
BLUE: 73.81 (+0.04), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34)
InvestorsObserver releases covered-call reports for Micron, bluebird bio Inc., Walgreens Boots Alliance, The Blackstone Group and Priceline
PR Newswire - Fri Sep 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, BX, MU, PCLN, and WBA.
BLUE: 73.81 (+0.04), MU: 17.66 (+0.74), WBA: 80.58 (-0.06), BX: 26.35 (+0.39), PCLN: 1,464.00 (+15.00)
bluebird bio Announces Webcast of Gene Therapy Day
BusinessWire - Fri Sep 09, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it will hold an analyst and investor day on October 13, 2016 in New York City, where the company will share updates on its progress in research and development, with a focus on hematopoietic stem cell programs. The event and live webcast will begin at 9:00 a.m. ET. To access the live webcast, please visit the "Events & Presentations" page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the event.
BLUE: 73.81 (+0.04)
bluebird bio Opens Phase 3 Study of LentiGlobin(TM) Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia
BusinessWire - Thu Sep 08, 7:15AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the opening of HGB-207, a Phase 3, global, multi-center study in patients with transfusion-dependent beta-thalassemia with non-B(0)/B(0) genotypes. This study will incorporate the addition of bluebird bio's transduction enhancers to the hematopoietic stem cell (HSC) manufacturing process, and will be conducted under the same Investigational New Drug application (IND) as previous studies of LentiGlobin in beta-thalassemia.
BLUE: 73.81 (+0.04)
Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., as President and Chief Business Officer
PR Newswire - Wed Sep 07, 9:17AM CDT
Oncorus®, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced the appointment of Cyrus D. Mozayeni, M.D., as President and Chief Business Officer. Dr. Mozayeni will provide strategic leadership for the company, as well as have responsibility for corporate development, finance, legal, human resources and business operations. Dr. Mozayeni will report to Mitchell H. Finer, Ph.D., Oncorus' Chief Executive Officer and Chief Scientific Officer.
BLUE: 73.81 (+0.04)
bluebird bio to Present at Four Upcoming Conferences
BusinessWire - Tue Aug 30, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences:
BLUE: 73.81 (+0.04)
How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma
PR Newswire - Wed Aug 10, 7:20AM CDT
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
BLUE: 73.81 (+0.04), ALDR: 35.12 (+0.98), SAGE: 46.25 (+0.38), RARE: 73.79 (-2.16)
bluebird bio to Present at Wedbush PacGrow Healthcare Conference
BusinessWire - Thu Aug 04, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Wedbush PacGrow Healthcare Conference on August 17, 2016 at 9:10 am ET. The conference is being held August 16-17, 2016 at the Le Parker Meridien in New York.
BLUE: 73.81 (+0.04)
bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress
BusinessWire - Wed Aug 03, 3:16PM CDT
--- Presented data on gene editing platform at American Society of Hematology (ASH) Workshop on Genome Editing -
BLUE: 73.81 (+0.04)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 73.81 (+0.04), SQNM: 2.39 (-0.01), TSRO: 107.56 (+2.77), NKTR: 19.15 (+0.18)
bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference
BusinessWire - Mon May 23, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Goldman Sachs 37th Annual Healthcare Conference on June 8, 2016 at 8:00 am PT (11:00 am ET). The conference is being held June 7-9, 2016 at the Terranea Resort in Rancho Palos Verdes, Calif.
BLUE: 73.81 (+0.04)
Join Victory Living Programs to Host 6th Annual Black and Blue Dine Around Event at Blue Martini and The Capital Grille in Fort Lauderdale
PR Newswire - Thu May 12, 9:00AM CDT
Victory Living Programs' Annual Black and Blue Dine Around event, held this year on Sunday, June 5, 2016 at 5:30 p.m., offers a unique dining and dancing experience complete with cocktails, dinner and dessert.
BLUE: 73.81 (+0.04)
bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon May 09, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its immuno-oncology and hematopoietic stem cell (HSC) gene therapy programs at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 73.81 (+0.04)
bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress
BusinessWire - Wed May 04, 3:05PM CDT
--- Ten abstracts accepted for presentation at American Society for Gene and Cell Therapy (ASGCT) Meeting -
BLUE: 73.81 (+0.04)
Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
Cory Renauer, The Motley Fool - Motley Fool - Tue May 03, 7:03AM CDT
Image source: bluebird bio. Against the mosaic of young, clinical-stage, gene-editing, cellular-therapy biotechs, bluebird bio (NASDAQ: BLUE) stands tall, despite its disdain for uppercase consonants. It has produced some amazing results in small...
BLUE: 73.81 (+0.04), BIIB: 312.00 (+4.95), VRTX: 91.82 (+0.13), MRK: 62.70 (+0.76)
Global Gene Therapy Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Advantagene, Bluebird Bio, Genethon - Research and Markets
BusinessWire - Tue Apr 26, 10:39AM CDT
Research and Markets has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering.
BLUE: 73.81 (+0.04)
LentiGlobin(TM) Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency's PRIME Program
BusinessWire - Wed Sep 21, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for LentiGlobin drug product in the treatment of patients with transfusion-dependent beta-thalassemia (TDT).
BLUE: 73.81 (+0.04)
InvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation
PR Newswire - Fri Sep 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ALDR, AMGN, BLUE, CSC, and EXPE.
BLUE: 73.81 (+0.04), ALDR: 35.12 (+0.98), CSC: 51.36 (+2.05), EXPE: 108.02 (+0.37), AMGN: 173.85 (+0.47)
bluebird bio (BLUE) in Focus: Stock Moves 11.4% Higher
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 7:25AM CDT
bluebird bio, Inc. (BLUE) moved big last session, as its shares jumped a little over 11% on the day.
BLUE: 73.81 (+0.04), GERN: 2.25 (+0.20)
bluebird bio Stock Up on Start of Phase III LentiGlobin Study
Zacks Equity Research - Zacks Investment Research - Fri Sep 09, 9:02AM CDT
bluebird bio, Inc. (BLUE) announced the commencement of a phase III study on its experimental gene therapy, LentiGlobin. Shares of the biotech company were up almost 9% yesterday on the news
BLUE: 73.81 (+0.04), CBM: 46.77 (+0.78), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34)
InvestorsObserver releases covered-call reports for Micron, bluebird bio Inc., Walgreens Boots Alliance, The Blackstone Group and Priceline
PR Newswire - Fri Sep 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, BX, MU, PCLN, and WBA.
BLUE: 73.81 (+0.04), MU: 17.66 (+0.74), WBA: 80.58 (-0.06), BX: 26.35 (+0.39), PCLN: 1,464.00 (+15.00)
bluebird bio Announces Webcast of Gene Therapy Day
BusinessWire - Fri Sep 09, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it will hold an analyst and investor day on October 13, 2016 in New York City, where the company will share updates on its progress in research and development, with a focus on hematopoietic stem cell programs. The event and live webcast will begin at 9:00 a.m. ET. To access the live webcast, please visit the "Events & Presentations" page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the event.
BLUE: 73.81 (+0.04)
bluebird bio Opens Phase 3 Study of LentiGlobin(TM) Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia
BusinessWire - Thu Sep 08, 7:15AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the opening of HGB-207, a Phase 3, global, multi-center study in patients with transfusion-dependent beta-thalassemia with non-B(0)/B(0) genotypes. This study will incorporate the addition of bluebird bio's transduction enhancers to the hematopoietic stem cell (HSC) manufacturing process, and will be conducted under the same Investigational New Drug application (IND) as previous studies of LentiGlobin in beta-thalassemia.
BLUE: 73.81 (+0.04)
Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., as President and Chief Business Officer
PR Newswire - Wed Sep 07, 9:17AM CDT
Oncorus®, Inc., a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced the appointment of Cyrus D. Mozayeni, M.D., as President and Chief Business Officer. Dr. Mozayeni will provide strategic leadership for the company, as well as have responsibility for corporate development, finance, legal, human resources and business operations. Dr. Mozayeni will report to Mitchell H. Finer, Ph.D., Oncorus' Chief Executive Officer and Chief Scientific Officer.
BLUE: 73.81 (+0.04)
bluebird bio to Present at Four Upcoming Conferences
BusinessWire - Tue Aug 30, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences:
BLUE: 73.81 (+0.04)
How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma
PR Newswire - Wed Aug 10, 7:20AM CDT
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
BLUE: 73.81 (+0.04), ALDR: 35.12 (+0.98), SAGE: 46.25 (+0.38), RARE: 73.79 (-2.16)
bluebird bio to Present at Wedbush PacGrow Healthcare Conference
BusinessWire - Thu Aug 04, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Wedbush PacGrow Healthcare Conference on August 17, 2016 at 9:10 am ET. The conference is being held August 16-17, 2016 at the Le Parker Meridien in New York.
BLUE: 73.81 (+0.04)
bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress
BusinessWire - Wed Aug 03, 3:16PM CDT
--- Presented data on gene editing platform at American Society of Hematology (ASH) Workshop on Genome Editing -
BLUE: 73.81 (+0.04)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 73.81 (+0.04), SQNM: 2.39 (-0.01), TSRO: 107.56 (+2.77), NKTR: 19.15 (+0.18)
bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference
BusinessWire - Mon May 23, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Goldman Sachs 37th Annual Healthcare Conference on June 8, 2016 at 8:00 am PT (11:00 am ET). The conference is being held June 7-9, 2016 at the Terranea Resort in Rancho Palos Verdes, Calif.
BLUE: 73.81 (+0.04)
Join Victory Living Programs to Host 6th Annual Black and Blue Dine Around Event at Blue Martini and The Capital Grille in Fort Lauderdale
PR Newswire - Thu May 12, 9:00AM CDT
Victory Living Programs' Annual Black and Blue Dine Around event, held this year on Sunday, June 5, 2016 at 5:30 p.m., offers a unique dining and dancing experience complete with cocktails, dinner and dessert.
BLUE: 73.81 (+0.04)
bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon May 09, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its immuno-oncology and hematopoietic stem cell (HSC) gene therapy programs at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 73.81 (+0.04)
bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress
BusinessWire - Wed May 04, 3:05PM CDT
--- Ten abstracts accepted for presentation at American Society for Gene and Cell Therapy (ASGCT) Meeting -
BLUE: 73.81 (+0.04)
Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
Cory Renauer, The Motley Fool - Motley Fool - Tue May 03, 7:03AM CDT
Image source: bluebird bio. Against the mosaic of young, clinical-stage, gene-editing, cellular-therapy biotechs, bluebird bio (NASDAQ: BLUE) stands tall, despite its disdain for uppercase consonants. It has produced some amazing results in small...
BLUE: 73.81 (+0.04), BIIB: 312.00 (+4.95), VRTX: 91.82 (+0.13), MRK: 62.70 (+0.76)
Global Gene Therapy Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Advantagene, Bluebird Bio, Genethon - Research and Markets
BusinessWire - Tue Apr 26, 10:39AM CDT
Research and Markets has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering.
BLUE: 73.81 (+0.04)
(0)
(0)Scroll down for more posts ▼